tetano
Editor, Senior Moderator
Scand J Infect Dis. 2014 Jul 8:1-4. [Epub ahead of print]
Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients.
Bickel M1, Lais C, Wieters I, Kroon FP, Doerr HW, Herrmann E, Brodt HR, Jung O, Allwinn R, Stephan C.
Author information
Abstract
The immune response after influenza vaccination is impaired in HIV-infected individuals and can be enhanced by a second dose. The durability of the antibody protection and its clinical benefit is not known. We investigated clinical symptoms and antibody titres against H1N1 influenza A following no dose, 1 dose, or 2 doses of an ASO3-adjuvanted H1N1 vaccine in HIV-infected patients. Seroprotection was found in 7.9%, 52.2%, and 57.3% of patients who received no dose, 1 dose, and 2 doses of the vaccine, respectively (p-value for group comparison < 0.001), after a median of 8.2 ? 1.6 months. Clinical symptoms suggestive of an influenza-like illness were slightly more frequently reported in the unvaccinated group. Vaccinated HIV-infected patients were more likely to be seroprotected at follow-up, but there was no difference comparing those who had received 1 or 2 doses of the vaccine.
KEYWORDS:
H1N1; HIV; adjuvanted; durability; pandemic
PMID:
25004089
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25004089
Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients.
Bickel M1, Lais C, Wieters I, Kroon FP, Doerr HW, Herrmann E, Brodt HR, Jung O, Allwinn R, Stephan C.
Author information
Abstract
The immune response after influenza vaccination is impaired in HIV-infected individuals and can be enhanced by a second dose. The durability of the antibody protection and its clinical benefit is not known. We investigated clinical symptoms and antibody titres against H1N1 influenza A following no dose, 1 dose, or 2 doses of an ASO3-adjuvanted H1N1 vaccine in HIV-infected patients. Seroprotection was found in 7.9%, 52.2%, and 57.3% of patients who received no dose, 1 dose, and 2 doses of the vaccine, respectively (p-value for group comparison < 0.001), after a median of 8.2 ? 1.6 months. Clinical symptoms suggestive of an influenza-like illness were slightly more frequently reported in the unvaccinated group. Vaccinated HIV-infected patients were more likely to be seroprotected at follow-up, but there was no difference comparing those who had received 1 or 2 doses of the vaccine.
KEYWORDS:
H1N1; HIV; adjuvanted; durability; pandemic
PMID:
25004089
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25004089